Sign In

Kyle Brewer

CEO and Founder at ETTA Biotechnology

Kyle Brewer is a scientist and entrepreneur currently working as the Associate Director of Advanced Drug Delivery and Regenerative Biomaterials at Stanford University.34 He holds a PhD in biophysics from the University of Texas Southwestern Medical Center, where he studied the structural model of the synaptotagmin-SNARE complex, proteins crucial for rapid neurotransmitter release.12

Brewer's academic background includes a BS in Biochemistry and a BA in Chemistry from North Carolina State University.12 During his undergraduate studies, he conducted research under Dr. Mitch Eddy at the NIH-National Institute of Environmental Health Sciences.12

At Stanford, Brewer has worked as a postdoctoral fellow in Dr. Tony Wyss-Coray's laboratory in the Department of Neurology and Neurological Sciences.1 He has also collaborated with Dr. Carolyn Bertozzi's laboratory in the Department of Chemistry and ChEM-H.12

Currently, as a Staff Scientist at Stanford's Advanced Drug Delivery and Regenerative Biomaterials (ADDReB) group, Brewer is recognized as an expert in RNA technology and mass spectroscopic bio-analytical techniques.2 He is working on the COL7A (collagen) project, which is likely related to his expertise in protein-protein and protein-lipid interactions.12

Brewer's research interests include cognition and longevity, with a focus on developing strategies to target brain aging, such as in Alzheimer's disease and other dementias.1 His work involves developing mouse models to study protein factors that may influence brain aging and rejuvenation.1

Highlights

Mar 14 · linkedin

Recruiting a Business Executive to Help Lead Stanford Startup Extending Healthy Human Lifespan

ETTA Biotechnology is an early-stage startup in Palo Alto, founded by a Stanford scientist with the goal of creating treatments targeting aging. Based on preclinical studies, our first treatments may extend healthy human lifespan by 10-30 years. London economists have estimated an intervention that can increase lifespan by 10 years is worth $367 trillion, the biggest economic opportunity in history. Our first clinical therapy is being developed for chronic kidney disease. Without a kidney transplant, chronic kidney disease leads to complete renal failure. Chronic kidney disease affects 1 in 7 people, and no medication exists specifically for the disease.

We are looking for a business executive to help lead the company. A successful candidate will have the opportunity to build and lead one of the most exciting businesses in the world. Responsibilities will include building relationships, fundraising, developing partnerships, and providing proven wisdom. Candidates with any of the experience below should consider reaching out.

• Deep business networks through prior experiences.

• Demonstrated ability to fundraise.

• Proven wisdom in business development.

Venture capital, startup, consulting, investment banking, or related experience is strongly preferred. Experience with preclinical or clinical development in the pharmaceutical, medical, or biotech industries is a big plus, but not necessarily required. Please contact Kyle Brewer at [email protected], briefly describing your background and interest to learn more.

Working hours are flexible. Remote/hybrid work is possible.

Related Questions

What are Kyle Brewer's main research interests?
How does Kyle Brewer's work contribute to the field of neurology?
What is the significance of the Wyss-Coray lab's research on young blood plasma transfusions?
How does Kyle Brewer's collaboration with Dr. Carolyn Bertozzi enhance his research?
What are the potential applications of Kyle Brewer's mouse model in treating Alzheimer's disease?
Kyle Brewer
Kyle Brewer, photo 1
Kyle Brewer, photo 2
Add to my network

Location

Palo Alto, California, United States